We recently discovered that MAT1A and GNMT were mostly expressed in the cytoplasm, whereas MAT2A showed both cytoplasmic and nuclear immunoreactivity, and that a higher cytoplasmic/nuclear (C/N) MAT2A expression ratio is correlated with poor overall survival in breast cancer patients [24]. This evidence concerns the gene MAT2A and breast carcinoma.